Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Zhongmou Therapeutics Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. Each action is associated with a distinct examiner and a distinct art unit.
MCLEOD, AFRICA MHAIRIE is the busiest examiner, with 1 pending action. The data supports matter-specific prosecution planning and does not show a repeated examiner or art-unit concentration.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
| SABILA, MERCY HELLEN | 1 | 57.5% | +45.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19334058 | USE OF MULTIPLE PROMOTERS EFFICIENTLY TARGETED ON ON-BIPOLAR CELLS IN GENE THERAPY TECHNOLOGY | MCLEOD, AFRICA MHAIRIE | — |
| 19310525 | NOVEL LIGHT-SENSITIVE CHANNEL PROTEIN VR2.0 AND USES THEREOF | SABILA, MERCY HELLEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19334058 | USE OF MULTIPLE PROMOTERS EFFICIENTLY TARGETED ON ON-BIPOLAR CELLS IN GENE THERAPY TECHNOLOGY | MCLEOD, AFRICA MHAIRIE | — |
| 19310525 | NOVEL LIGHT-SENSITIVE CHANNEL PROTEIN VR2.0 AND USES THEREOF | SABILA, MERCY HELLEN | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19334058 | USE OF MULTIPLE PROMOTERS EFFICIENTLY TARGETED ON ON-BIPOLAR CELLS IN GENE THERAPY TECHNOLOGY | MCLEOD, AFRICA MHAIRIE | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 19, 2025 |
| 19310525 | NOVEL LIGHT-SENSITIVE CHANNEL PROTEIN VR2.0 AND USES THEREOF | SABILA, MERCY HELLEN | 1654 | §102§112 | Non-Final OA | — | Pending | Aug 26, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhongmou Therapeutics Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Africa Mhairie Mcleod has the most, with 1 of Zhongmou Therapeutics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
